Company / Capital Returned to Shareholders per Share
Neurocrine Biosciences Capital Returned to Shareholders per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders per Share
$1.69
FY2025
5-year range
$0.00 / $3.04
FY2023-FY2025
Trend
-44.5%
vs FY2024
Sector context
#18 of 51
Health Care
What the data says
At $1.69, Neurocrine Biosciences's capital returned to shareholders per share ranks #18 of 51 in the Health Care sector. Improved from $0.00 to $1.69 over the past 2 years.
Based on SEC 10-K filings.
1.69 in FY2025.
Improved from $0.00 to $1.69 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#18 of 51 in Health CareTop 35% of 51This company $1.69 Sector average $2.74
▼
-38.3% below sector average
Key checks
Key Insights
- In FY2025, capital returned to shareholders per share decreased 44.5% year-over-year.
- Ranks #18 out of 51 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to Shareholders per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.69 | -44.5% |
| FY2024 | $3.04 | - |
| FY2023 | $0.00 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026